Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS
July 19, 2022 07:00 ET
|
Clene Inc.
SALT LAKE CITY, July 19, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial
July 14, 2022 07:00 ET
|
Clene Inc.
As of the July 5, 2022, data cutoff, early CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths vs. 14 placebo deaths, HR=0.301, p=0.0143)CNM-Au8 treatment was...
Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28
June 27, 2022 07:00 ET
|
Clene Inc.
SALT LAKE CITY, June 27, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Nanomedicine’s Patent Portfolio Grows to More Than 150 Issued Worldwide, including Two Key Patents Now Validated Across Europe
December 15, 2021 07:00 ET
|
Clene Inc.
Powerful combination of key patents comes as the Company looks ahead to topline results from a Phase 3 registration study in ALS in second half of 2022 SALT LAKE CITY, Dec. 15, 2021 (GLOBE...
Clene Nanomedicine’s Facility Improvement Project Receives $1 Million Grant Award from the Maryland Department of Housing and Community Development (DHCD)
December 13, 2021 07:00 ET
|
Clene Inc.
Clene Nanomedicine’s Maryland facility is among the projects and activities awarded fundingThe manufacturing expansion is in preparation for anticipated commercialization SALT LAKE CITY, Dec. 13,...
Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in Late-Breaking Session at 32nd International Symposium on ALS/MND
December 10, 2021 07:00 ET
|
Clene Inc.
Late-breaker oral presentation by Professor Steve Vucic, University of Sydney Medical School and Northcott Chair of NeurologyCNM-Au8®demonstrated significantly slowed disease progression, decreased...
Clene Nanomedicine’s RESCUE-ALS Phase 2 Results Selected for Late-Breaking Presentation at 32nd International Symposium on ALS/MND
December 07, 2021 07:00 ET
|
Clene Inc.
Late-breaker oral presentation by Professor Steve Vucic, University of Sydney Medical School and Northcott Chair of NeurologyCNM-Au8® demonstrated significantly slowed disease progression:...
Clene Nanomedicine Presents Updated Data from RESCUE-ALS Phase 2 Study at 4th Annual ALS ONE Research Symposium
December 01, 2021 07:00 ET
|
Clene Inc.
CNM-Au8 has favorable impact on progression of ALS as measured by joint rank comparison of combined survival and ALSFRS-R change – a clinically meaningful endpoint recommended by the FDACNM-Au8 showed...
Clene Announces Completion of Patient Enrollment in the HEALEY ALS Platform Trial
November 15, 2021 08:48 ET
|
Clene Inc.
Registration trial for CNM-Au8®, a gold nanocrystal suspensionTopline data anticipated 2H 2022World’s first ALS platform trial accelerating the path to new ALS therapies SALT LAKE CITY, Nov. 15,...
Clene Reports Third Quarter 2021 Operating and Financial Highlights
November 09, 2021 07:00 ET
|
Clene Inc.
Recently announced top-line results from RESCUE-ALS Phase 2 trial with CNM-Au8®, a gold nanocrystal suspensionVISIONARY-MS blinded interim data show clinically relevant improvements in the modified MS...